Cohort study
Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma
- Retrospective cohort study
- population-based
- SEER-Medicare registry
Authors' conclusion
In this study, preexisting HF in patients with newly diagnosed DLBCL was common and was associated with lower use of anthracyclines and lower use of any chemotherapy.
Study context
- Population
- Individuals ≥65 years with newly diagnosed diffuse large B-cell lymphoma (DLBCL), 2000–2015, with continuous Medicare Part A or B in the prior year
- Participants
- 30,728 individuals
- Exposure
- Preexisting heart failure (HF) vs no preexisting HF
- Preexisting HFn = 4,266
- Outcome
- Anthracycline-based treatment
Main finding
As reported in the abstract
Odds ratio
0.55
95% CI 0.49–0.61
Preexisting HF vs Without preexisting HF
OR 0.55 (95% CI 0.49–0.61)
Observational data: associations, not effects.
Secondary outcomes
| Outcome | Preexisting HF | Without preexisting HF | HR (95% CI) | |
|---|---|---|---|---|
| Lymphoma mortality · 1 year · adjusted for baseline and time-varying treatment factors | 41.8% (95% CI 40.5–43.2) | 29.6% (95% CI 29.0%–30.1%) | 1.24 (1.18–1.31) | |
| 0.512Hazard ratio (log scale) |
- Prevalence of preexisting HF at lymphoma diagnosis
- 13.9% · 4266 of 4266
- Dexrazoxane or liposomal doxorubicin use (preexisting HF receiving an anthracycline)
- 7.0% · 78 of 4266
Original publication
Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma. JAMA Cardiol. Published 1 May 2023. doi:10.1001/jamacardio.2023.0303
Summarised from the published abstract; every number is checked against it